TAEST 16001

Drug Profile

TAEST 16001

Alternative Names: Anti-NY-ESO-1 TCR transduced T cells; NY-ESO-1-specific TCR affinity enhancing specific T cell therapy; TAEST-16001; TCR affinity enhancing specific T cell therapy

Latest Information Update: 25 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Guangzhou Institute of Respiratory Disease
  • Developer Guangdong Xiangxue Precision Medical Technology; Guangzhou Institute of Respiratory Disease; Guangzhou Xiangxue Pharmaceuticals; Xiangxue Life Science Research Center
  • Class Antineoplastics; Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 17 May 2017 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in China (IV) (NCT03159585)
  • 20 Jan 2017 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Recurrent) in China (Parenteral) (NCT03029273)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top